2024
Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)
Karam S, Amouzegar A, Alshamsi I, Al Ghamdi S, Anwar S, Ghnaimat M, Saeed B, Arruebo S, Bello A, Caskey F, Damster S, Donner J, Jha V, Johnson D, Levin A, Malik C, Nangaku M, Okpechi I, Tonelli M, Ye F, Abu-Alfa A, Savaj S, Authors R, Abou-Jaoudeh P, Al Hussain T, Al Salmi I, Alrukhaimi M, Alyousef A, Bahous S, Cai G, Hassan H, Cho Y, Davids M, Davison S, Diongole H, Divyaveer S, Ekrikpo U, Ethier I, Fung W, Ghimire A, Hooman N, Houston G, Htay H, Ibrahim K, Irish G, Jindal K, Kelly D, Lalji R, Mitwali A, Mortazavi M, Nalado A, Neuen B, Olanrewaju T, Osman M, Ossareh S, Petrova A, Riaz P, Saad S, Sakajiki A, See E, Sozio S, Tiv S, Tungsanga S, Viecelli A, Wainstein M, Wannous H, Yeung E, Zaidi D. Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney International Supplements 2024, 13: 57-70. PMID: 38618498, PMCID: PMC11010631, DOI: 10.1016/j.kisu.2024.01.009.Peer-Reviewed Original ResearchChronic kidney disease registryImprovement of early detectionHealth-related quality-of-life scoresLower health-related quality-of-life scoresGlobal Kidney Health AtlasChronic kidney diseaseHealth information systemsConservative kidney managementLevels of careBurden of kidney diseaseQuality-of-life scoresPrevalence of chronic kidney diseaseManagement of kidney failureIncidence of kidney transplantationKidney failure treated with dialysisSymptom burdenKidney diseaseKidney managementPeritoneal dialysisTailored guidelinesKidney transplantationKidney failureMiddle East regionEast regionRegistryAn update on the global disparities in kidney disease burden and care across world countries and regions
Bello A, Okpechi I, Levin A, Ye F, Damster S, Arruebo S, Donner J, Caskey F, Cho Y, Davids M, Davison S, Htay H, Jha V, Lalji R, Malik C, Nangaku M, See E, Sozio S, Tonelli M, Wainstein M, Yeung E, Johnson D, Group I, Abu-Alfa A, Amouzegar A, Anand S, Arogundade F, Ashuntantang G, Bavanandan S, Coppo R, Diongole H, Divyaveer S, Ekrikpo U, Ethier I, Fung W, Gaipov A, Ghimire A, Houston G, Ibrahim K, Irish G, Jindal K, Kelly D, Lightstone L, Madero M, Nalado A, Neuen B, Olanrewaju T, Osman M, Parekh R, Petrova A, Prasad N, Prikhodina L, Racki S, Riaz P, Saad S, Sakajiki A, Savaj S, Shah D, Suzuki Y, Tesar V, Tiv S, Tungsanga S, Tzanno-Martins C, Viecelli A, Wang A, Wong M, Zaidi D. An update on the global disparities in kidney disease burden and care across world countries and regions. The Lancet Global Health 2024, 12: e382-e395. PMID: 38365413, DOI: 10.1016/s2214-109x(23)00570-3.Peer-Reviewed Original ResearchConceptsConservative kidney managementLow-resource settingsCountry income levelKidney replacement therapyKidney careHealth workforce shortagesWHO building blocksLiterature review of published reportsGlobal Kidney Health AtlasWorld Bank income groupsKidney care deliveryBurden of chronic kidney diseaseBurden of kidney diseaseGlobal burden of kidney diseaseAnnual median costsChronic kidney diseaseHigh-income countriesKidney disease burdenPhases of data collectionPrevalence of chronic kidney diseaseIncome levelPoint of deliveryAffordability of medicinesCare deliveryWorkforce shortagesImpact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
Elkeraie A, Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaedi A, AlSuwaida A, Arici M, Ecder T, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective. International Journal Of Nephrology And Renovascular Disease 2024, 17: 1-16. PMID: 38196830, PMCID: PMC10771977, DOI: 10.2147/ijnrd.s430532.Peer-Reviewed Original ResearchChronic kidney diseaseSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsDiabetes mellitusKidney diseaseType 2 diabetes mellitusMajor public health concernAldosterone system inhibitorsBetter clinical outcomesCause of deathPublic health concernNephrology referralCKD managementClinical outcomesSystem inhibitorsCardioprotective propertiesEarly initiationTreatment pathwaysConsensus recommendationsHigh riskPatientsBetter careHealth concernEarly detectionHypertension
2023
Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches
Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaaidi A, AlSuwaida A, Arici M, Ecder T, Koraie A, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches. International Journal Of Nephrology And Renovascular Disease 2023, 16: 103-112. PMID: 37051319, PMCID: PMC10084934, DOI: 10.2147/ijnrd.s363133.Peer-Reviewed Original ResearchChronic kidney diseaseManagement of CKDChronic kidney disease managementKidney disease managementManagement of patientsNovel therapeutic optionsTherapeutic optionsKidney diseaseProtective therapyOverall burdenEarly diagnosisAvailable evidenceDisease managementHealthcare specialistsHealthcare systemHealthcare policyPatientsSteering CommitteeBurdenRiskHypertensionComorbiditiesDiabetesReferralTherapy
2021
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East
Amouzegar A, Abu-Alfa AK, Alrukhaimi MN, Bello AK, Ghnaimat MA, Johnson DW, Jha V, Harris DCH, Levin A, Tonelli M, Lunney M, Saad S, Khan M, Zaidi D, Osman MA, Ye F, Okpechi IG, Ossareh S, Board I. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East. Kidney International Supplements 2021, 11: e47-e56. PMID: 33981470, PMCID: PMC8084726, DOI: 10.1016/j.kisu.2021.01.002.Peer-Reviewed Original ResearchChronic kidney diseaseKidney replacement therapyKidney diseaseKidney failureKidney careReplacement therapyNephrology Global Kidney Health AtlasNondialysis chronic kidney diseaseGlobal Kidney Health AtlasPeritoneal dialysis servicesHealth care fundingKidney transplantationDialysis RegistryKidney functionTransplantation servicesHigh burdenPermanent impairmentDialysis servicesDisease strategiesHemodialysis servicesHealth information systemsHealth AtlasSustainable health information systemsDiseaseCare fundingControversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Babitt J, Eisenga M, Haase V, Kshirsagar A, Levin A, Locatelli F, Małyszko J, Swinkels D, Tarng D, Cheung M, Jadoul M, Winkelmayer W, Drüeke T, Participants C, Abu-Alfa A, Afsar B, Pai A, Besarab A, Moore G, Casadevall N, Cases A, de Francisco A, Eckardt K, Fishbane S, Fried L, Ganz T, Ginzburg Y, Gómez R, Goodnough L, Hamano T, Hanudel M, Hao C, Iseki K, Ix J, Johansen K, Ketteler M, Kovesdy C, Leaf D, Macdougall I, Massy Z, McMahon L, Minutolo R, Nakanishi T, Nemeth E, Obrador G, Parfrey P, Park H, Pecoits-Filho R, Robinson B, Roger S, Shah Y, Spinowitz B, Tanaka T, Tsukamoto Y, Tungsanga K, Walther C, Wang A, Wolf M. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International 2021, 99: 1280-1295. PMID: 33839163, DOI: 10.1016/j.kint.2021.03.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseAnemia guidelinesHypoxia-inducible factor prolyl hydroxylase inhibitorOptimal anemia managementErythropoiesis-stimulating agentsTreatment of anemiaIron homeostasisSignificant adverse consequencesControversies ConferenceIron therapyAnemia managementRandomized trialsDiagnostic challengePatient outcomesEpidemiological studiesHydroxylase inhibitorTreatment targetsGlobal outcomeLatest evidenceDiseaseAnemiaPrevious recommendationsAdverse consequencesOngoing controversy
2020
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
Małyszko J, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Porta C, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař V, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International 2020, 98: 1407-1418. PMID: 33276867, DOI: 10.1016/j.kint.2020.07.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseHematological malignanciesControversies ConferenceKidney transplantationModerate stage chronic kidney diseaseKDIGO Controversies ConferenceAcute kidney injuryKidney transplant recipientsBurden of cancerKidney injuryTransplant recipientsKidney transplantRegistry analysisMultiple myelomaClinical challengeCancer riskGlobal outcomeMalignancyCancerPatientsDiseaseTransplantationBidirectional relationshipRiskKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
Porta C, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Małyszko J, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař L, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney International 2020, 98: 1108-1119. PMID: 33126977, DOI: 10.1016/j.kint.2020.06.046.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseSolid organ malignanciesControversies ConferenceKidney impairmentKidney diseaseKidney cancerKDIGO Controversies ConferenceSetting of malignancyIncidence of cancerAreas of controversyOrgan malignanciesTreatment landscapeKidney functionOncology patientsMedical oncologyPalliative careRenal issuesPatient outcomesNovel therapiesCritical careMalignancyAnticancer treatmentCancerPatientsCancer treatmentFramework for establishing integrated kidney care programs in low- and middle-income countries
Tonelli M, Nkunu V, Varghese C, Abu-Alfa AK, Alrukhaimi MN, Bernieh B, Fox L, Gill J, Harris D, Hou F, O’Connell P, Rashid H, Niang A, Ossareh S, Tesar V, Zakharova E, Yang C. Framework for establishing integrated kidney care programs in low- and middle-income countries. Kidney International Supplements 2020, 10: e19-e23. PMID: 32149006, PMCID: PMC7031683, DOI: 10.1016/j.kisu.2019.11.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic kidney diseaseKidney care programKidney replacement therapyKidney failureKidney diseaseKidney careMiddle-income countriesReplacement therapyCare programAcute kidney injuryUrgent public health needPublic health needsKidney injuryKidney transplantationPrimary preventionPreventive careRisk factorsNoncommunicable diseasesTimely managementKidney disordersHealth needsMild formHealth systemDiseaseTherapy
2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
House A, Wanner C, Sarnak M, Piña I, McIntyre C, Komenda P, Kasiske B, Deswal A, deFilippi C, Cleland J, Anker S, Herzog C, Cheung M, Wheeler D, Winkelmayer W, McCullough P, Participants C, Abu-Alfa A, Amann K, Aonuma K, Appel L, Baigent C, Bakris G, Banerjee D, Boletis J, Bozkurt B, Butler J, Chan C, Costanzo M, Dubin R, Filippatos G, Gikonyo B, Gikonyo D, Hajjar R, Iseki K, Ishii H, Knoll G, Lenihan C, Lentine K, Lerma E, Macedo E, Mark P, Noiri E, Palazzuoli A, Pecoits-Filho R, Pitt B, Rigatto C, Rossignol P, Setoguchi S, Sood M, Störk S, Suri R, Szummer K, Tang S, Tangri N, Thompson A, Vijayaraghavan K, Walsh M, Wang A, Weir M. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 95: 1304-1317. PMID: 31053387, DOI: 10.1016/j.kint.2019.02.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseDialysis-dependent chronic kidney diseaseNondialysis chronic kidney diseaseHeart failureKidney diseaseEjection fractionGlobal outcomeKidney transplant patientsReduced ejection fractionControversies ConferenceTransplant patientsBreakout group discussionsDiseaseOutcomesFailureHFpEFPatientsGroup discussionsPrevalenceIncidenceDiagnosisPrevention
2013
Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients
Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. American Journal Of Physiology. Renal Physiology 2013, 305: f613-f617. PMID: 23825072, DOI: 10.1152/ajprenal.00173.2013.BooksConceptsChronic kidney diseaseKidney diseaseBariatric surgeryModerate chronic kidney diseaseWeight reduction regimensIntentional weight lossRenal functional changesWeight loss interventionHigh-protein dietGlomerular hyperfiltrationPerioperative complicationsObese patientsRenal damageLoss interventionAdvanced stageFunctional changesModest riskWeight lossDiseaseAlbuminuriaObesityPatientsSurgeryBeneficial reductionHypertension
2008
Nephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosisThe association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*
Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*. Current Medical Research And Opinion 2008, 24: 1091-1100. PMID: 18328118, DOI: 10.1185/030079908x280653.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseErythropoiesis-stimulating agentsHealth-related qualityDarbepoetin alfaWeek 52Week 12Kidney diseasePatients' health-related qualityGeneral CKD populationQ2W darbepoetin alfaWeek darbepoetin alfaGlomerular filtration rateSingle-arm studyBenefits of treatmentMean Hb concentrationYears of ageSubject inclusion criteriaCKD populationCreatinine clearanceHemoglobin levelsHb targetHb levelsHRQOL measuresFiltration rateInclusion criteriaThe Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio